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Abstract Objective To analyze the association between the indirect methods of evaluating
insulin resistance (IR) and blood pressure, anthropometric and biochemical parameters
in a population of polycystic ovary syndrome (PCOS) patients.
Methods Cross-sectional study performed at the Hospital Universitário de Brasília
(HUB, in the Portuguese acronym) involving PCOS patients diagnosed from Janu-
ary 2011 to January 2013. Four indirect methods, namely, fasting blood insulin level,
fasting glucose/insulin ratio (G/I), homeostatic model-assessment-insulin resistance
(HOMA-IR), and the quantitative insulin sensitivity check index (QUICKI), were used to
obtain the IR diagnosis. The data were analyzed using the test of proportions, the Chi-
square test, and Fisher exact test, when indicated.
Results Out of the 83 patients assessed, aged 28.79  5.85, IR was found in 51.81–
66.2% of them using the G/I ratio and the QUICKI, respectively. The test of proportions
did not show a signiﬁcant difference between the methods analyzed. The proportion
of IR diagnoses was statistically higher in obese women than in women with normal
body mass index (BMI). We observed a statistically signiﬁcant association between all
the methods for diagnosing IR and BMI, waist circumference (WC) and lipid
accumulation product (LAP). With regards to arterial hypertension (AH), we observed
a signiﬁcant association according to three methods, with the exception of the ratio
G/I.
Conclusion Insulin resistance prevalence varied according to the diagnostic method
employed, with no statistical difference between them. The proportion of IR diagnoses
was statistically higher in obese women than in women with normal BMI. We observed
a signiﬁcant association between IR andWC, BMI, LAP, as well as dyslipidemia and AH in
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Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder affecting women in childbearing age. It
is a heterogeneous disorder whose pathogenesis is not well
understood despite evidence of complex interaction with
genetic, behavioral and environmental factors that contrib-
ute to its occurrence.1
Threedistinctdiagnosticcriteriahavebeenused,namely, the
National Institutes of Health (NIH), the Rotterdam consensus,
and the Androgen Excess and PCOS Society (AE-PCOS) criteria.
The previous exclusion of pathologies presenting a similar
clinical picture is important for all three diagnostic criteria.1
In addition to being an ovulatory disorder, PCOS can also
be considered a metabolic disorder, since insulin resistance
(IR) and consequent compensatory hyperinsulinemia, which
are closely related to its pathogenicity and comorbidities, can
be exacerbated by the coexistence of obesity, which affects
 50% of PCOS women.2
However, IR is not part of the diagnostics criteria, partly
and probably because of the absence of an accurate validated
method for use in clinical practice, since the hyperinsuline-
mic-euglycemic clamp, the gold standard for diagnosing IR, is
expensive and difﬁcult to perform.3
It has been observed that, in addition to IR, PCOS patients
are at a higher risk of developing glucose intolerance, Type 2
Diabetes Mellitus, dyslipidemia, and metabolic syndrome
(MS),1,2 all of which are traditional risk factors for the
development of cardiovascular diseases (CVDs).
Nevertheless, there remain uncertainties regarding the
clinical outcomes and mortality due to CVD.4 Furthermore,
the fact that these patients are predominantly young and
often show normal lipid proﬁle could be contributing to
delays in their evaluation and in the adequate establishment
of their clinical management.1,5
The purpose of this paper is to analyze the association
between the indirect methods of evaluating IR and the blood
pressure, anthropometric and biochemical parameters in a
population of PCOS patients.
Methods
A cross-sectional study was performed at the Hospital Uni-
versitário de Brasília (HUB, in the Portuguese acronym) using
information obtained from the records of patients diagnosed
with PCOS from January 2011 to January 2013.
Thepopulationof thestudy includedwomen18yearsofage
or older with a PCOS diagnosis according to the Rotterdam
criteria.5 Cases of thyroid dysfunction, hyperprolactinemia,
congenital adrenal hyperplasia, Cushing syndrome, glucose
intolerance, diabetes, ovarian or adrenal tumors, premature
ovarian failure, patients who had used any hormonal or non-
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Resumo Objetivo Analisar a associação entre os métodos indiretos de avaliação de resistência
à insulina (RI) e parâmetros pressóricos, antropométricos e bioquímicos em uma
população de pacientes com síndrome dos ovários policísticos (SOP).
Métodos Estudo transversal realizado no Hospital Universitário de Brasília (HUB),
envolvendo pacientes que apresentaram o diagnóstico de SOP no período de janeiro de
2011 a janeiro de 2013. O diagnóstico de RI foi obtido por meio de quatro métodos
indiretos: insulinemia de jejum, relação glicemia de jejum/insulinemia de jejum (G/I),
avaliação da resistência à insulina através do modelo homeostático (HOMA-IR) e índice
quantitativo de sensibilidade à insulina (QUICKI). Os dados foram analisados utilizando
o teste de proporções, o teste do Qui-quadrado e o teste exato de Fisher, quando
indicado.
Resultados Foram avaliadas 83 pacientes com idade média de 28,79  5,85 anos. A
RI foi diagnosticada em 51,81–66,27% dos casos pela relação G/I e QUICKI, respectiva-
mente, e o teste de proporções não evidenciou diferença signiﬁcativa entre osmétodos
analisados. A proporção de diagnósticos de RI foi estatisticamente maior em mulheres
obesas em comparação à proporção de mulheres com índice de massa corporal (IMC)
normal. Foi observada uma associação estatisticamente signiﬁcativa entre todos os
métodos diagnósticos de RI e IMC, circunferência da cintura (CC) e produto de
acumulação lipídica (LAP). Quanto à hipertensão arterial (HA), foi observada asso-
ciação signiﬁcativa de acordo com três métodos, com exceção da relação G/I.
Conclusão A prevalência de RI variou conforme o método diagnóstico utilizado, mas
não houve diferença estatística entre eles. A proporção de diagnósticos de IR foi maior
nas mulheres obesas do que naquelas com peso normal. Foi observada associação
signiﬁcativa entre RI e CC, IMC e LAP, assim como com dislipidemia e HA em uma
proporção elevada de pacientes.
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hormonal medication that could interfere with the results
during the 6monthsprior to thestudy, patients under18years
of age, and records lacking any of the information required
were excluded from the study.
In addition to demographic data, such as marital status,
parity and age, the analysis included menstrual patterns, the
existence of hyperandrogenism, acne, and acanthosis nigri-
cans. Menstrual cycles were considered anovulatory when
longer than 35 and shorter than 90 days, and amenorrheic in
the absence of menstruation for at least 3 months,6 while
hirsutism was deﬁned as a Ferriman and Gallwey7 score of
eight or more. Total blood testosterone was obtained using
the chemiluminescence method, with values exceeding 80
ng/dL considered altered.
The analysis of the anthropometricmeasurements includ-
ed the body mass index (BMI) and the waist circumference
(WC). The BMI was obtained using the Quetelet8 index,
namely, the ratio of weight over height in square meters,
and the results were subdivided into normal (18.5–24.9),
overweight (25–29.9) and obese ( 30). The WC was the
smallest circumference between the last rib and the iliac
crest,8 with a cutting point at 88 cm.9
Blood pressure (BP) and biochemical evaluation, through
the analysis of the concentration of triglycerides, total cho-
lesterol, high-density lipoprotein cholesterol (HDL-c), low
density lipoprotein cholesterol (LDL-c), lipoproteins exclud-
ing HDL cholesterol (non-HDL-c), and fasting glucose were
also evaluated. The parameters of normality, as well as the
diagnostic criteria of MSwere deﬁned.9 In addition, the lipid
accumulation product (LAP),10 which uses an anthropomet-
ric measurement (waist circumference) and a biochemical
measurement (triglycerides), was also calculated and con-
sidered normal when lower than 34.5.11
Insulin Resistance was diagnosed using four indirect
methods, namely, fasting blood insulin in excess of 12 µIU/
mL,12 the fasting blood glucose over fasting blood insulin
ratio lower than 6.4,12 homeostatic model assessment-insu-
lin resistance(HOMA-IR), calculated using the Mathews for-
mula,13 higher than 2.71,14 and quantitative insulin
sensitivity check index(QUICKI) lower than 0.333.12
The Chi-square test (X2) or the Fisher exact test (where
recommended) were used to evaluate the association be-
tween the four indirect methods of evaluating IR and the
blood pressure, anthropometric and biochemical param-
eters. Contingency tables were performed with IR diagnos-
tic method and the BMI classiﬁed into groups (normal,
overweight and obesity), and the test for equality of pro-
portions was used to identify which groups were different
from one another in terms of IR. The test of proportions was
also used to evaluate the differences between the frequen-
cies among the four IR diagnostic methods. The SAS 9.3
statistical software package (SAS Institute, Cary, NC, USA)
was used and considered statistically signiﬁcant when
p 0.05.
The study was approved by the Committee of Ethics
in Research in Human Beings of the Faculdade de
Ciências da Saúde da Universidade de Brasília (CAAE
14168613.3.0000.0030).
Results
After applying the inclusion and exclusion criteria, 83 PCOS
patients were included in the study. Age varied from 18 to
42 years-old, 44.57% of patients being single and 51.8%
nulliparous. In the clinical evaluation, 96.39% of the patients
reported oligomenorrhea or amenorrhea, 73.49%, hirsutism
(Ferriman-Gallwey index), 48.19%, acanthosis nigricans,
43.37%, acne and one patient reported androgenic alopecia.
Total testosterone exceeded 80 ng/dL in 18.29% of the
patients, and 70 ng/dL in 50.60% of them. The clinical,
anthropometric, blood pressure, and biochemical results
are shown in ►Table 1.
Insulin resistance was diagnosed in 66.27% of the cases
using the QUICKI; in 60.24% by the fasting blood insulin; in
59.04% by the HOMA-IR; and in 51.81% by the fasting
glucose/insulin (G/I) ratio. With regards to the frequency
of IR, there was no signiﬁcant difference among the methods
analyzed according to the test of proportions (p ¼ 0.304). As
shown in ►Table 2, there was a statistically signiﬁcant
association between BMI and all the IR diagnostic methods,
aswell as between IR andWC. Regarding high bloodpressure,
no signiﬁcant association was found for the G/I.
Obesity and overweight were diagnosed in 56.62% and
24.09% of the patients, respectively. Comparing the BMI
groups two by two, the prevalence of IR was higher among
Table 1 Anthropometric, blood pressure and biochemical
characteristics of the 83 patients with polycystic ovary
syndrome
Parameters Mean  Standard
Deviation
Reference
Age (years) 28.79  5.85
Weight (Kg) 76.43  13.91
Height (cm) 160.12  6.63
Ferriman-Gallwey
score
11.83  2.94 < 8
Body mass index 29.9  5.28 18–25 kg/m2
Waist
circumference
92.15  10.72 < 88 cm
Systolic blood
pressure




79.13  11.00 < 85 mm Hg
Total cholesterol 183.07  34.88  200 mg/dL
High-density
lipoprotein
49.47  12.91  50 mg/dL
Low-density
lipoprotein
117.16  32.74 < 100 mg/dL
Non-HDL
lipoproteins
133.41  35.17 < 130 mg/dL
Triglycerides 110.6  59.09 < 150 mg/dL
Fasting blood
glucose
87.74  6.52 < 100 mg/dL
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the obese patients regardless of the indirect method used,
varying from 68.09–82.98% using the G/I and the QUICKI,
respectively. In overweight women, IR varied from 50–55%,
while in normal BMI women, the highest IR value was 25%,
according to the QUICKI, and the lowest value was 18.75%, as
per the other three methods.
►Table 3 shows that the proportion of IR diagnoses was
statistically higher in obesewomenwhen comparedwith the
proportion of normal BMI patients in all methods of assess-
ment. There was no difference in proportions of IR among
normal weight and overweight women.
With regards to the biochemical parameters, the associa-
tion between IR and the non-HDL-c level was statistically
signiﬁcant according to the QUICKI, while in the case of the
triglycerides a statistical signiﬁcancewas found in the fasting
blood insulin and theQUICKI (►Table 4).►Table 4 also shows
a statistically signiﬁcant association among all the IR diag-
nostic methods and the LAP.
An analysis of the isolated parameters showed that 22.89%
of the patients presented at least three diagnostic criteria for
MS. And the X2 test showed a statistically signiﬁcant associ-
ation between those cases and all the IR diagnostic methods
with p ¼ 0.0005 for fasting insulin, p ¼ 0.0070 for the G/I,
p ¼ 0.0021 for the HOMA-IR, and p ¼ 0.0004 for the QUICKI.
Discussion
Polycystic ovary syndrome is one of the most common
endocrine pathologies of women of bearing-age. Although
its prevalence could be even higher when the Rotterdam
diagnostic criteria5 are followed, a large percentage of the
cases might not be diagnosed at the primary health service
level.1,15 Also, these patients might not receive due attention
from the metabolic and cardiovascular points of view,
Table 2 Association between insulin resistance and the anthropometric and blood pressure parameters in 83 patients with
polycystic ovary syndrome
Method BMI WC SBP DBP AH
Fasting insulinemia < 0.0001 < 0.0001 0.0019 0.0099 0.0118
G/I 0.0014 < 0.0001 0.1225 0.2308 0.2866
HOMA-IR 0.0002 < 0.0001 0.0051 0.0252 0.0253
QUICKI 0.0001 < 0.0001 0.0057 0.0591 0.0348
Abbreviations: AH, arterial hypertension; BMI, body mass index; DBP, diastolic blood pressure; G/I, fasting blood glucose/fasting blood insulin ratio;
HOMA-IR, homeostatic model assessment-insulin resistance; QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure; WC,
waist circumference.
Chi-square test. Signiﬁcant association (p < 0.05).
(Full data are available in the supplemental ﬁle).
Table 3 Test of proportions for the body mass index groups as









0.1117 < 0.0001 0.0395
G/I 0.3119 0.0017 0.0611
HOMA-IR 0.1117 0.0001 0.0629
QUICKI 0.0779 < 0.0001 0.0881
Abbreviations: G/I, fasting blood glucose/fasting blood insulin ratio;
HOMA-IR, homeostatic model assessment- insulin resistance; QUICKI,
quantitative insulin sensitivity check index.
(Full data are available in the supplemental ﬁle).
Test of proportions; Signiﬁcant difference between the proportions
(p < 0.05).
Table 4 Association between insulin resistance diagnostic methods and the lipid accumulation product and biochemical variables
in polycystic ovary syndrome patients
Method LAP Total Choles-
terol
HDL-c LDL-c Non-HDL-c TG
Fasting Insulinemia 0.0001 0.4863 0.1149 0.6782 0.0941 0.0099 #
G/I 0.0001 0.1148 0.2689 0.6922 0.0816 0.1579 #
HOMA-IR 0.0001 0.4107 0.1786 0.5686 0.1448 0.0750 #
QUICKI 0.0001 0.2657 0.1623 0.9134 0.0190 0.0252 #
Abbreviations: G/I, fasting blood glucose/fasting blood insulin ratio; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model
assessment-insulin resistance; LAP, lipid accumulation product; LDL-c, low-density lipoprotein cholesterol; Non- HDL-c, non–HDL cholesterol; QUICKI,
quantitative insulin sensitivity check index; TG, triglycerides.
(Full data are available in the supplemental ﬁle).
Chi-square test. Signiﬁcant association (p < 0.05).

#Fisher exact test. Signiﬁcant association (p < 0.05).
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because their management tends to focus on their aesthetic
and reproductive problems.1
Although its physiopathology is not quite understood,
there is no doubt that IR plays an important role, since it
leads to compensatory hyperinsulinemia with complex
effects on the regulation of lipid metabolism, protein syn-
thesis and modulation of androgen production,16 whose
mechanism results from a defect in the insulin receptor
characterized by increased serine phosphorylation.3
Nevertheless, the prevalence of IR has been an object of
discussion. In our study, IR was found in 51.81–66.27% of the
patients, depending on the diagnostic method employed, but
it has been diagnosed in 50–80% of PCOS patients.1,12,16 Such
great variability may result from the diagnostic criteria used
in PCOS, different PCOS phenotypes, ethnic differences in
insulin action, or even environmental factors such as diet, as
well as the method used to identify IR.3
Because the complexity and cost of the hyperinsulinemic-
euglycemic clamp for IR diagnosis make its use impractical
for routine use in clinical practice,3 other measures have
been employed, such as HOMA-IR, QUICKI and the G/I,3,12
which appear effective in diagnosing IR.12 However, despite
the statement that the HOMA-IR and QUICKI would be more
sensitive in detecting IR,12 we have not observed a statisti-
cally signiﬁcant difference among the four methods used in
our study.
Insulin resistance may be found in PCOS patients with
normal weight, but its frequency and magnitude increase in
the presence of obesity.1,2,17 The average frequency of IR was
20.31% among normal weight patients, 50% among over-
weight patients and 76.59% among obese patients in our
study. We also observed a signiﬁcantly higher proportion of
IR among the obese patients when compared with normal
weight patients. These ﬁndings are similar to those of Reyes-
Muñoz et al18 using HOMA. In addition, Moran et al17
observed a strong positive correlation between the magni-
tude of IR, measured using the G/I, and the women’s BMI.
Obesity is an independent risk factor of developing CD and
it has been suggested that, independently from the BMI,
PCOS women tend to accumulate fat in the visceral abdomi-
nal region, which confers them a metabolic risk.1
In our study, there was a statistically signiﬁcant associa-
tion between both anthropometric factors— BMI and WC—
and all the IR diagnostic methods. An extensive review
published recently19 observed that the greatest health impli-
cations for PCOS patients are associated with excess weight
and abdominal circumference, since visceral abdominal fat is
associated with increasing IR.19
It has been observed that IR could promote CD directly
and/or, indirectly, through changes in ﬁbrinolysis,
compromising lipolysis suppression and inducing arterial
hypertension (AH).4
A Swedish study found that, even in the absence of a true
hypertensive state, PCOS women had higher average blood
pressure than the controls, even after adjusting for the BMI
and body fat distribution20 and a Brazilian study observed
the prevalence of AH two times higher in PCOS women than
in non-PCOS women.21 In our study, we observed a statisti-
cally signiﬁcant association between AH and IR with three of
the four diagnostic methods employed.
It has also been suggested that IR could contribute to the
dyslipidemia frequently observed in PCOS patients through
various mechanisms. While Slowińska-Srzednicka et al22
observed a positive correlation between total triglycerides
and fasting insulin and a negative correlation between
apolipoprotein A-I and fasting insulin in PCOS women, our
study showed a signiﬁcant association between the triglyc-
eride levels and IR diagnosed using the QUICKI and the
fasting blood insulin level. Furthermore, the frequent ﬁnding
of high non-HDL-c in PCOS patients, seen in 53.01% of the
cases in our study, also reﬂects another cardiovascular risk
factor in these women.19
Although dyslipidemia can occur independently of obesi-
ty,23 BMI is believed to be the main determining factor for
high triglyceride levels and reduced HDL levels, frequently
found in PCOS.24
However, the LDL-c in PCOS seems less dependent on
body weight and could be partially related to the hyper-
androgenism frequently observed in thesewomen.1,19 In our
study, 73.49% of the patients showed hirsutism and in 18.29%
of them total plasma testosterone exceeded 80 ng/dL. Nev-
ertheless, although the high LDL-c levels could be associated
with hyperandrogenism, it is not clear whether there is a
causal relation between them.1 Furthermore, the androgens
could also contribute to IR by means of a direct effect on
skeletal muscle and action on adipose tissue.3
It has also been reported that the menstrual pattern of
these patients could contribute to the IR ﬁnding. Brower
et al25 observed that, in PCOS women, when the menstrual
cycle exceeded 35 days, HOMA-IR levels were higher than
those of the controls or of PCOS women with regular cycles.
In our study, 55.43% of the patients showed such menstrual
cycle pattern and 40.96% were amenorrheic. Acanthosis
nigricans, observed in 48.19% of the patients, cannot be
forgotten, since a substantial percentage of PCOS patients
suffer from this condition and its severity correlates with
the degree of IR.26
Besides that, the metabolic abnormalities in PCOS
patients can coincide with the diagnostic components of
the MS,9 in which IR and compensatory hyperinsulinemia
also play a crucial role in the physiopathology of the MS.27
Nevertheless, the prevalence of this syndrome can vary
depending on the ethnicity, age, BMI, country, as well as
the criteria used in deﬁning both PCOS and theMS.28Despite
having excluded the analysis the patients’ charts with fasting
glucose higher than 100 mg/dL, 22.89% of the patients in our
study had at least three parameters altered the normalcy
standards, which would comply with the MS diagnostic
criteria,9 reinforcing the higher cardiovascular risk in PCOS
women.
In addition, we observed a statistically signiﬁcant associ-
ation between all the indirect methods of diagnosing IR and
the presence of at least three diagnostic parameters for MS.
The most prevalent association involved high WC (68.67%)
and low HDL (50%). These ﬁndings are similar to those of
Madani et al,28 who also observed a higher prevalence of
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those two criteria, although decreased HDL was the most
frequently observed alteration in their study.
The LAP index, combining the WC measurement and the
triglyceride levels, was initially tested in 2005. The results
suggested that it could become a predictor of CD incidence.10
The LAP has been shown to bemore accurate than HOMA-
IR in the diagnosis of IR.29 While Macut et al30 observed an
association between HOMA-IR and LAP, we observed a
statistically signiﬁcant association between LAP and all the
methods of diagnosing IR. So that LAP could be an indicator of
IR and other possible comorbidities related to this metabolic
disorder, including CD in PCOS patients, in agreement with
the previously observed ﬁndings.11 Nascimento et al31 cor-
roborated this statement in a study of PCOS patients inwhich
the researchers found an association between LAP and vari-
ous cardiovascular risk parameters.
Some limitations in our study should be mentioned,
particularly concerning the diagnosis of PCOS and MS. In
regard to MS, we used internationally accepted criteria,9 and
although we did not use the ﬁve classic measures for MS
diagnosis, since fasting blood glucose level was excluded
from the statistical analysis, we did use the other four to
demonstrate the important metabolic disorders occurring in
these patients and the signiﬁcant association with IR.
Although the new PCOS guidelines suggest modiﬁcations
in one of the diagnostic criteria by increasing the number of
follicles to 25 because of new technologies for ultrasonogra-
phy examination, the ovary size was not inﬂuenced by this
innovation and 10 cm3 is still the cut-off point between a
normal and an increased ovary.32 Thus, we based our diag-
noses on the size of the ovary alone, rather than in the
number of follicles. In addition, the guidelines of the Endo-
crine Society issued in 2013 suggested the use of the
Rotterdam criteria for the diagnosis of PCOS.33
The gold standard in the diagnosis of IR is the hyper-
insulinemic-euglycemic clamp. Nevertheless, this method is
too expensive and elaborate for use in clinical practice. The
diagnosis was established using four indirect methods, and it
has been shown the mathematical methods, such as HOMA-
IR and QUICKI, have a good correlation with the clamp.12,34
Furthermore, they are sensitive enough to detect IR in
PCOS.12 In addition, no statistical differences were found
among the four methods, which could facilitate the initial
identiﬁcation of the patients suffering from IR at the primary
health care level. Thus, more complex calculations would be
avoided, and the patients referred to other speciﬁc clinical
evaluations much sooner.
It is also important to mention that this study evaluated
an institutional rather than a population-based sample, so
the real prevalence of IR and cardiovascular risk factors in
PCOSwomen could not be determined. Also, even though we
have observed various associations between IR and these
factors, like others in the literature,11,18,28,30 the cross-
sectional design cannot infer causal relationships between
IR, obesity, dyslipidemia and PCOS.
Another limitation, albeit unrelated to the study per se,
results from the possible repercussions of the ﬁndings. The
average age of the patients was 28.79 years, similarly to that
of other studies in the literature.15,28,30,31 It could be as-
sumed, therefore, that the existence of high metabolic risk in
the young PCOS patients could predispose them to CD as they
grow older.19
However, the actual incidence of CD and mortality is still
under dispute.While a 21-year follow-up study of a cohort of
Swedish PCOS patients did not ﬁnd increased myocardial
infarct, stroke or mortality, despite the higher prevalence of
AHand dyslipidemia in thesewomen,35 a prospective Iranian
studywith a 12-year follow-up of PCOS patients and controls
did not ﬁnd any signiﬁcant difference in the cardiac-meta-
bolic risk factors between the two groups.4 Besides that, it
was also found that the difference in insulin levels and IR,
initially higher in the PCOS group, diminished along time.4
Nevertheless, a recent meta-analysis observed a signiﬁcant
association between PCOS and coronary heart disease, al-
though no association was found between PCOS and myo-
cardial infarction.36
It is possible that the heterogeneous nature of the PCOS,
the lack of knowledge about its physiopathology and the
existence of exogenous factors and other confounding ele-
ments, such as obesity, make it difﬁcult to evaluate with
any degree of precision the extension of the long-term
complications of the syndrome.19 In addition, changes in
metabolic regulation and ovarian function could also modify
the expression of the disease and act over its morbidity.19
Nevertheless, despite the controversies about the future
of these patients, we cannot ignore the ﬁndings of our study:
a series of independent and associated factors of cardiovas-
cular risk, such as the existence of IR and its signiﬁcant
association with WC, BMI, LAP, as well as dyslipidemia and
AH in a high proportion of patients.
Early detection of those metabolic and cardiovascular
risk factors by the primary health care services through the
use of simple measures, such as the anthropometric evalu-
ation of the patients and LAP, would lead to appropriate
counseling regarding the patients’ lifestyle or to the pre-
scription of medications that could improve their quality of
life and reduce the risk of PCOS’ long term complications,
which increase considerably the costs of the health care
provided.
Conclusion
Insulin resistance was found in 51.81–66.2% of the patients,
with no signiﬁcant difference between the four methods
analyzed. The proportion of IR diagnoses was statistically
higher in obese women than in women with normal BMI. A
statistically signiﬁcant association was observed between IR
and WC, BMI, LAP, as well as dyslipidemia and AH in a high
proportion of patients.
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